FOLD Stock - Amicus Therapeutics, Inc.
Unlock GoAI Insights for FOLD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $528.29M | $399.36M | $329.23M | $305.51M | $260.89M |
| Gross Profit | $475.35M | $362.03M | $290.63M | $271.05M | $229.84M |
| Gross Margin | 90.0% | 90.7% | 88.3% | 88.7% | 88.1% |
| Operating Income | $24.88M | $-77,211,000 | $-212,120,000 | $-206,434,000 | $-246,998,000 |
| Net Income | $-56,106,000 | $-151,584,000 | $-236,568,000 | $-250,460,000 | $-276,852,000 |
| Net Margin | -10.6% | -38.0% | -71.9% | -82.0% | -106.1% |
| EPS | $-0.18 | $-0.51 | $-0.82 | $-0.92 | $-1.07 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Visit WebsiteEarnings History & Surprises
FOLDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $0.13 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.12 | $0.17 | +41.7% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.02 | $0.01 | -50.0% | ✗ MISS |
Q2 2025 | May 1, 2025 | $0.08 | $0.03 | -62.5% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $0.02 | $0.09 | +350.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.08 | $0.10 | +25.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.05 | $0.06 | +9.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.06 | $-0.02 | +66.7% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.06 | $-0.11 | -83.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.13 | $-0.18 | -38.5% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.19 | $-0.12 | +36.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.24 | $-0.30 | -25.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.14 | $-0.29 | -107.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Latest News
Frequently Asked Questions about FOLD
What is FOLD's current stock price?
What is the analyst price target for FOLD?
What sector is Amicus Therapeutics, Inc. in?
What is FOLD's market cap?
Does FOLD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FOLD for comparison